Clinical Trial Update: Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 results assess the efficacy and safety of anlotinib as adjuvant therapy for high-grade soft tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Fudan University | Conditions: Soft Tissue Sarcoma Adult, High Grade Sarcoma | Phase 2 | Status: COMPLETED